Is Trevogrumab legal in the United Kingdom?

Trevogrumab in the United Kingdom at a glance

Classification and note come from the Trevogrumab profile, checked against Medicines and Healthcare products Regulatory Agency (MHRA) listings at the reviewed date.

What this means

• 01

  Trevogrumab is being studied in registered clinical trials but has not received MHRA marketing approval in the United Kingdom.

• 02

  Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.

• 03

  Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.

What Trevogrumab is

Regeneron's anti-myostatin antibody, alone or with the anti-activin antibody garetosmab, preserved 51% to 81% of lean mass during semaglutide weight loss in the COURAGE trial, at the cost of more adverse events.

The COURAGE Phase 2 tested semaglutide alone, with trevogrumab (blocks myostatin/GDF8), and with both trevogrumab and garetosmab (blocks activin A). 3% over semaglutide alone.

Mechanism: Trevogrumab neutralizes myostatin (GDF8); garetosmab neutralizes activin A. Both ligands restrain muscle growth, and activin A also promotes fat storage.

Regulatory history: Investigational (obesity)

How MHRA treats this kind of product

Licenses medicines for the UK market. A compound without a marketing authorisation is an unlicensed medicine, which can only lawfully be supplied for human use through a prescriber under the specials scheme, not sold as a research product.

The classification above is the The Longevity Archive reading of Medicines and Healthcare products Regulatory Agency listings for Trevogrumab at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.

Trevogrumab in other countries

Frequently asked questions

Related compounds in the United Kingdom